Differential Expression of Immune Checkpoints TIM-3, LAG-3, TIGIT, and Siglec-7 on Circulating Natural Killer Cells – Insights from Healthy Donors Compared to Gastric Cancer Patients
Our findings suggest the potential of LAG-3 as a next-generation checkpoint molecule, alongside Siglec-7. Especially targeting the sialic acid-Siglec-7 axis may offer promising therapeutic strategies for various cancer types in the future. .
Authors
- Justus Körfer
- Sabine Seiffert (ORCID: https://orcid.org/0000-0002-6850-4796)
- Ulrike Koehl (ORCID: https://orcid.org/0000-0002-8159-9160)
- Ulrich Sack (ORCID: https://orcid.org/0000-0002-7813-0492)
- André‐René Blaudszun (ORCID: https://orcid.org/0000-0002-0208-6894)
- Benjamin Shibru
- Stephan Fricke (ORCID: https://orcid.org/0009-0004-2413-2208)
- Andreas Boldt
Institutions
- Dbe Technology (Germany) (DE)
- Fraunhofer Institute for Cell Therapy and Immunology (DE)
- Klinikum Chemnitz (DE)
- Leipzig University (DE)
Publication Details
- Journal
- Oncology Research and Treatment
- Published
- 2025-04-03
- DOI
- https://doi.org/10.1159/000545429
- Citations
- 4
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 3.19